Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
|Slideshows|June 17, 2015
10 FDA-Approved Drugs for Primary Care
Author(s)Grace Halsey
Since January 2015, the FDA has approved more than a dozen drugs indicated for primary care diseases. Here, a quick slide update on 10 of them.
Advertisement
Since January 2015, the FDA has approved more than a dozen medications indicated for primary care diseases. In the slides above, a brief look at 10 of the newest approvals, starting with the most recent.
Advertisement
Related to this article
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
Advertisement
Advertisement
Trending on Patient Care Online
1
Mediterranean Diet Linked to Lower Odds of Adult Acne in New Study
2
4 FDA Decisions for Primary Care to Know from October 2026
3
Why a Negative Endometrial Biopsy May Not End the Abnormal Bleeding Workup
4
New Schizophrenia Treatment Addresses Long-Standing LAI Barriers
5